OncoMatch/Clinical Trials/NCT07471776
Study on Using TROP2-PET and 18F-FDG PET to Predict the Efficacy of Anti TROP2 ADC Treatment in Advanced Breast Cancer
Is NCT07471776 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Sacituzumab Govitecan、Datopotamab deruxtecan、Sacituzumab tirumotecan for metastatic breast cancer ( her2 negative).
Treatment: Sacituzumab Govitecan、Datopotamab deruxtecan、Sacituzumab tirumotecan — This study aims to evaluate whether \^68Ga-TROP2 PET/CT, combined with \^18F-FDG PET/CT, can predict the efficacy of anti-TROP2 antibody-drug conjugates in patients with advanced HER2-negative breast cancer. Baseline and dynamic imaging parameters will be used to develop prediction models (primary endpoint: AUC), and their associations with clinical outcomes and tumor TROP2 status will be explored.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Breast Carcinoma
Biomarker criteria
Required: HER2 (ERBB2) negative (HER2-negative)
HER2-negative breast cancer
Required: TACSTD2 imaging avidity
protocol-defined ^68Ga-TROP2 PET/CT
Disease stage
Metastatic disease required
Prior therapy
Cannot have received: antibody-drug conjugate (sacituzumab govitecan, datopotamab deruxtecan)
prior exposure to an anti-TROP2 ADC
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07471776 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior antibody-drug conjugate disqualifies patients from enrollment.
Does this trial require ERBB2?
Yes, ERBB2 negative is a required biomarker for enrollment.
Does this trial require TACSTD2?
Yes, TACSTD2 imaging avidity is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages